vs
Avantor, Inc.（AVTR）与Quanterix Corp（QTRX）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Quanterix Corp的37.9倍（$1.7B vs $43.9M）。Avantor, Inc.净利率更高（3.1% vs -52.7%，领先55.9%）。Quanterix Corp同比增速更快（24.7% vs -1.4%）。Avantor, Inc.自由现金流更多（$117.2M vs $-16.5M）。过去两年Quanterix Corp的营收复合增速更高（16.9% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Quanterix Corp是一家生命科学企业，研发、生产和销售超高灵敏度单分子检测诊断平台、试剂及检测服务，覆盖肿瘤、神经退行性疾病、传染病等领域，为全球科研机构、生物制药企业及临床实验室提供研究、药物开发及临床诊断相关支持。
AVTR vs QTRX — 直观对比
营收规模更大
AVTR
是对方的37.9倍
$43.9M
营收增速更快
QTRX
高出26.1%
-1.4%
净利率更高
AVTR
高出55.9%
-52.7%
自由现金流更多
AVTR
多$133.7M
$-16.5M
两年增速更快
QTRX
近两年复合增速
-0.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $43.9M |
| 净利润 | $52.4M | $-23.1M |
| 毛利率 | 31.5% | 45.7% |
| 营业利润率 | 7.6% | -56.4% |
| 净利率 | 3.1% | -52.7% |
| 营收同比 | -1.4% | 24.7% |
| 净利润同比 | -89.5% | -98.8% |
| 每股收益（稀释后） | $0.08 | $-0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRQTRX
| Q4 25 | $1.7B | $43.9M | ||
| Q3 25 | $1.6B | $40.2M | ||
| Q2 25 | $1.7B | $24.5M | ||
| Q1 25 | $1.6B | $30.3M | ||
| Q4 24 | $1.7B | $35.2M | ||
| Q3 24 | $1.7B | $35.8M | ||
| Q2 24 | $1.7B | $34.4M | ||
| Q1 24 | $1.7B | $32.1M |
净利润AVTRQTRX
| Q4 25 | $52.4M | $-23.1M | ||
| Q3 25 | $-711.8M | $-33.5M | ||
| Q2 25 | $64.7M | $-30.0M | ||
| Q1 25 | $64.5M | $-20.5M | ||
| Q4 24 | $500.4M | $-11.6M | ||
| Q3 24 | $57.8M | $-8.4M | ||
| Q2 24 | $92.9M | $-7.4M | ||
| Q1 24 | $60.4M | $-11.2M |
毛利率AVTRQTRX
| Q4 25 | 31.5% | 45.7% | ||
| Q3 25 | 32.4% | 42.8% | ||
| Q2 25 | 32.9% | 46.2% | ||
| Q1 25 | 33.8% | 54.1% | ||
| Q4 24 | 33.4% | 63.0% | ||
| Q3 24 | 32.9% | 56.3% | ||
| Q2 24 | 34.1% | 64.7% | ||
| Q1 24 | 34.0% | 57.8% |
营业利润率AVTRQTRX
| Q4 25 | 7.6% | -56.4% | ||
| Q3 25 | -40.0% | -92.8% | ||
| Q2 25 | 7.7% | -151.6% | ||
| Q1 25 | 9.3% | -86.9% | ||
| Q4 24 | 37.8% | -42.0% | ||
| Q3 24 | 7.3% | -32.8% | ||
| Q2 24 | 10.3% | -31.8% | ||
| Q1 24 | 8.7% | -47.3% |
净利率AVTRQTRX
| Q4 25 | 3.1% | -52.7% | ||
| Q3 25 | -43.8% | -83.3% | ||
| Q2 25 | 3.8% | -122.6% | ||
| Q1 25 | 4.1% | -67.6% | ||
| Q4 24 | 29.7% | -33.1% | ||
| Q3 24 | 3.4% | -23.3% | ||
| Q2 24 | 5.5% | -21.5% | ||
| Q1 24 | 3.6% | -34.8% |
每股收益（稀释后）AVTRQTRX
| Q4 25 | $0.08 | $-0.48 | ||
| Q3 25 | $-1.04 | $-0.73 | ||
| Q2 25 | $0.09 | $-0.77 | ||
| Q1 25 | $0.09 | $-0.53 | ||
| Q4 24 | $0.73 | $-0.30 | ||
| Q3 24 | $0.08 | $-0.22 | ||
| Q2 24 | $0.14 | $-0.19 | ||
| Q1 24 | $0.09 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $29.8M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $5.6B | $295.7M |
| 总资产 | $11.8B | $418.8M |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资AVTRQTRX
| Q4 25 | $365.4M | $29.8M | ||
| Q3 25 | $251.9M | $38.3M | ||
| Q2 25 | $449.4M | $132.9M | ||
| Q1 25 | $315.7M | $76.5M | ||
| Q4 24 | $261.9M | $56.7M | ||
| Q3 24 | $285.3M | $29.3M | ||
| Q2 24 | $272.6M | $47.0M | ||
| Q1 24 | $234.9M | $45.3M |
总债务AVTRQTRX
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.3B | — |
股东权益AVTRQTRX
| Q4 25 | $5.6B | $295.7M | ||
| Q3 25 | $5.6B | $314.5M | ||
| Q2 25 | $6.3B | $292.5M | ||
| Q1 25 | $6.1B | $316.4M | ||
| Q4 24 | $6.0B | $330.0M | ||
| Q3 24 | $5.6B | $338.9M | ||
| Q2 24 | $5.4B | $340.8M | ||
| Q1 24 | $5.3B | $343.4M |
总资产AVTRQTRX
| Q4 25 | $11.8B | $418.8M | ||
| Q3 25 | $11.7B | $444.1M | ||
| Q2 25 | $12.8B | $375.6M | ||
| Q1 25 | $12.3B | $396.5M | ||
| Q4 24 | $12.1B | $406.5M | ||
| Q3 24 | $12.8B | $411.0M | ||
| Q2 24 | $12.7B | $415.9M | ||
| Q1 24 | $12.8B | $414.2M |
负债/权益比AVTRQTRX
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $-16.4M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $-16.5M |
| 自由现金流率自由现金流/营收 | 7.0% | -37.7% |
| 资本支出强度资本支出/营收 | 2.1% | 0.2% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | $-80.0M |
8季度趋势，按日历期对齐
经营现金流AVTRQTRX
| Q4 25 | $152.7M | $-16.4M | ||
| Q3 25 | $207.4M | $-41.2M | ||
| Q2 25 | $154.4M | $-5.7M | ||
| Q1 25 | $109.3M | $-13.9M | ||
| Q4 24 | $173.3M | $-4.3M | ||
| Q3 24 | $244.8M | $-5.7M | ||
| Q2 24 | $281.1M | $-5.0M | ||
| Q1 24 | $141.6M | $-20.2M |
自由现金流AVTRQTRX
| Q4 25 | $117.2M | $-16.5M | ||
| Q3 25 | $171.7M | $-41.9M | ||
| Q2 25 | $124.8M | $-6.4M | ||
| Q1 25 | $81.3M | $-15.1M | ||
| Q4 24 | $145.8M | $-4.7M | ||
| Q3 24 | $204.0M | $-6.6M | ||
| Q2 24 | $235.3M | $-6.5M | ||
| Q1 24 | $106.9M | $-20.7M |
自由现金流率AVTRQTRX
| Q4 25 | 7.0% | -37.7% | ||
| Q3 25 | 10.6% | -104.2% | ||
| Q2 25 | 7.4% | -26.3% | ||
| Q1 25 | 5.1% | -49.9% | ||
| Q4 24 | 8.6% | -13.4% | ||
| Q3 24 | 11.9% | -18.4% | ||
| Q2 24 | 13.8% | -19.1% | ||
| Q1 24 | 6.4% | -64.5% |
资本支出强度AVTRQTRX
| Q4 25 | 2.1% | 0.2% | ||
| Q3 25 | 2.2% | 1.7% | ||
| Q2 25 | 1.8% | 3.2% | ||
| Q1 25 | 1.8% | 4.1% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 2.7% | 4.7% | ||
| Q1 24 | 2.1% | 1.6% |
现金转化率AVTRQTRX
| Q4 25 | 2.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.69× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 4.24× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 2.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
QTRX
| Products | $29.2M | 67% |
| Consumable And Other Products | $12.7M | 29% |
| Service Type Warranties | $1.7M | 4% |
